Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People With Type 1 Diabetes.

Eva SvehlikovaNicole L AshcroftChristina GatschelhoferDavid GerringVera HöllerJan JezekBettina LacknerFiona LawrenceVijay PillaiMaria RatzerMartina UrschitzMichael WolfThomas R Pieber

Published in: Diabetes care (2023)

AT278 U500 offers rapid-acting characteristics in a reduced dose volume, with accelerated absorption and onset of action compared with IAsp U100 in the studied population.

Keyphrases

double blind
type diabetes
placebo controlled
clinical trial
drug delivery
glycemic control
loop mediated isothermal amplification
phase iii
study protocol
phase ii
randomized controlled trial
metabolic syndrome
insulin resistance
skeletal muscle
weight loss